Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 84Leukemia 49Lymphoma 21Burkitt Lymphoma 19Leukemia, Biphenotypic, Acute 14Leukemia, Myeloid, Acute 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Extranodal NK-T-Cell 7Recurrence 6Lymphoma, Non-Hodgkin 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Myelodysplastic Syndromes 4Dendritic Cell Sarcoma, Interdigitating 4Neoplasm, Residual 3Down Syndrome 3Anemia, Refractory, with Excess of Blasts 3Myeloproliferative Disorders 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Monocytic, Acute 2Leukemia, Erythroblastic, Acute 2Leukemia, Eosinophilic, Acute 2Anemia, Refractory 2Thrombocytopenia 1Sarcoma, Myeloid 1Pancreatic Neoplasms 1Neutropenia 1Neoplasms 1Nasopharyngeal Carcinoma 1

Interventions

Dexamethasone 3iniparib 2Poly(ADP-ribose) Polymerase Inhibitors 2Calcium Dobesilate 2dexamethasone acetate 1dexamethasone 21-phosphate 1asparaginase erwinia chrysanthemi recombinant 1amminedichloro(2-methylpyridine)platinum(II) 1ZD4054 1Vincristine 1Sodium Chloride 1Rituximab 1Paclitaxel 1Narrow Band Imaging 1Methotrexate 1Doxorubicin 1Dexrazoxane 1Cytarabine 1Carboplatin 1BNT162 Vaccine 1Asparaginase 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hypersensitivity × Asparaginase × Clear all
NCT00928200 2019-02-19

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1 Terminated
1 enrolled 7 charts
LymphoidOther hematologic neoplasm

Hypersensitivity, Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡